Side Effects of Approved Molecular Targeted Therapies
Posted: Sat Jan 05, 2008 2:02 am
New article for the people who is/thinking about antiangiogenic targeted therapies is published in The Oncologist 2007;12:1443–1455
Review: Side Effects of Approved Molecular Targeted Therapies in
Solid Cancers
http://theoncologist.alphamedpress.org/ ... 12/12/1443
it is an updated review of the side effects of Anti-EGFR agents • Anti-HER-2 agents • Anti-VEGFR agents such as
Gefitinib - inhibitor of EGFR
Erlotinib - inhibitor of EGFR
Cetuximab Monoclonal antibody - Block EGFR
Panitumumab Monoclonal antibody- Block EGFR
Trastuzumab Monoclonal antibody - Block HER-2
Lapatinib - Inhibition of EGFR and HER-2
Bevacizumab Monoclonal antibody - Block VEGF
Sorafenib (BAY 43–9006) - multitargeted TK inhibitor Inhibition of VEGFR-2, VEGFR-3, PDGFRB, Raf, c-Kit, and Flt-3
Sunitinib (SU 11248) - multitargeted TK inhibitor Inhibition of VEGFR, PDGFR, cKit, and Flt-3
Review: Side Effects of Approved Molecular Targeted Therapies in
Solid Cancers
http://theoncologist.alphamedpress.org/ ... 12/12/1443
it is an updated review of the side effects of Anti-EGFR agents • Anti-HER-2 agents • Anti-VEGFR agents such as
Gefitinib - inhibitor of EGFR
Erlotinib - inhibitor of EGFR
Cetuximab Monoclonal antibody - Block EGFR
Panitumumab Monoclonal antibody- Block EGFR
Trastuzumab Monoclonal antibody - Block HER-2
Lapatinib - Inhibition of EGFR and HER-2
Bevacizumab Monoclonal antibody - Block VEGF
Sorafenib (BAY 43–9006) - multitargeted TK inhibitor Inhibition of VEGFR-2, VEGFR-3, PDGFRB, Raf, c-Kit, and Flt-3
Sunitinib (SU 11248) - multitargeted TK inhibitor Inhibition of VEGFR, PDGFR, cKit, and Flt-3